(Q34388686)

1 August 2017

title

Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease (English)

1 reference

1 August 2017

1 reference

2

Susan H Fox

1 reference

1 August 2017

Barbara Connolly

1

1 reference

1 August 2017

publication date

1 January 2014

1 reference

1 August 2017

1 reference

1 August 2017

volume

11

1 reference

1 August 2017

issue

1

1 reference

1 August 2017

page(s)

78-91

1 reference

Diagnosis and treatment of impulse control disorders in patients with movement disorders

1 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Measuring mild cognitive impairment in patients with Parkinson's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Antidepressants for depression in Parkinson's disease: systematic review and meta-analysis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Nonpharmacological enhancement of cognitive function in Parkinson's disease: a systematic review

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Apathy in Parkinson's disease: diagnosis, neuropsychological correlates, pathophysiology and treatment

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Parkinson disease psychosis: Update

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Neurobiology of cognitive impairment in Parkinson's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Underlying neurobiology and clinical correlates of mania status after subthalamic nucleus deep brain stimulation in Parkinson's disease: a review of the literature

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Telephone-based cognitive-behavioral therapy for depression in Parkinson disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Depression in Parkinson disease--epidemiology, mechanisms and management.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Mood disorders in Parkinson's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Atypical antipsychotic drugs in the treatment of Parkinson's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

An update expert opinion on management and research strategies in Parkinson's disease psychosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Parkinson's disease: the quintessential neuropsychiatric disorder

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

The trajectory of apathy after deep brain stimulation: from pre-surgery to 6 months post-surgery in Parkinson's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Efficacy of Rivastigmine on Executive Function in Patients with Parkinson's Disease Dementia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Anxiety disorders in Parkinson's disease: prevalence and risk factors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

The epidemiology of dementia associated with Parkinson disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Randomized controlled trial of memantine in dementia associated with Parkinson's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Relationship between depression and cognitive dysfunctions in Parkinson's disease without dementia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Overview of the extranigral aspects of Parkinson disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

A controlled trial of antidepressants in patients with Parkinson disease and depression

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Impulse control and related disorders in Parkinson's disease: review

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Efficacy and safety of galantamine (reminyl) in the treatment of dementia in patients with Parkinson's disease (open-label controlled trial)

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia: a retrospective analysis of a double-blind trial and an open-label extension

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

A systematic review of prevalence studies of depression in Parkinson's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Long-term follow-up of impulse control disorders in Parkinson's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

The hallucinating brain: a review of structural and functional neuroimaging studies of hallucinations

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Metabolic alterations in patients with Parkinson disease and visual hallucinations

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

The impact of depressive symptoms in early Parkinson disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Clinical diagnostic criteria for dementia associated with Parkinson's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with dementia and dementia with Lewy bodies.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Cognitive behavioural therapy (CBT) for carers of patients with Parkinson's disease: a preliminary randomised controlled trial.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Rivastigmine for dementia associated with Parkinson's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Motivation, reward, and Parkinson's disease: influence of dopatherapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

6 July 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

6 July 2018

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

What contributes to quality of life in patients with Parkinson's disease?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Emergency department presentations of patients with Parkinson's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Evolution of mild cognitive impairment in Parkinson disease.

6 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Cognitive profile of patients with newly diagnosed Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Cognitive impairment in Parkinson disease: impact on quality of life, disability, and caregiver burden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Efficacy and safety of donepezil in the treatment of executive dysfunction in Parkinson disease: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Effects of methylphenidate on cognitive function and gait in patients with Parkinson's disease: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Benefits of rivastigmine on attention in dementia associated with Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Improving memory in Parkinson's disease: a healthy brain ageing cognitive training program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

A 12-year population-based study of psychosis in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Pharmacological treatment of deep brain stimulation-induced hypomania leads to clinical remission while preserving motor benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Dementia and visual hallucinations associated with limbic pathology in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Serotonin 2A receptors and visual hallucinations in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Risperidone and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Olanzapine treatment for dopaminergic-induced hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Mortality in Parkinson's disease and its association with dementia and depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

The relationship of depression and disease stage to patient perceptions of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Caregiver distress associated with neuropsychiatric problems in patients with early Parkinson's disease: the Norwegian ParkWest study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Prevalence of depression in Parkinson's disease: effects of disease stage, motor subtype and gender

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

SSRIs in the treatment of depression in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Bupropion in the treatment of depression in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Bitemporal electroconvulsive therapy for depression in a Parkinson disease patient with a deep-brain stimulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

The independent influence of apathy and depression on cognitive functioning in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Apathy may herald cognitive decline and dementia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Apathy in patients with Parkinson disease as a function of side of onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Impulsive and compulsive behaviors in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Dopamine agonist withdrawal syndrome in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Zonisamide in managing impulse control disorders in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Effects of donepezil on compulsive hypersexual behavior in Parkinson disease: a single case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Clozapine for medication‐related pathological gambling in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Topiramate in managing impulse control disorders in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Disabling repetitive behaviors in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Pathologic gambling in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Amantadine may reverse punding in Parkinson's disease--observation in a patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Clozapine as a potential treatment for refractory impulsive, compulsive, and punding behaviors in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Management of punding in Parkinson's disease: an open-label prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Does Nefazodone Improve Both Depression and Parkinson Disease? A Pilot Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

Dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-013-0238-X

The DONPAD-study--treatment of dementia in patients with Parkinson's disease with donepezil

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Low-dose cyproterone acetate treatment of sexual acting out in men with dementia

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

Effect of reboxetine on depression in Parkinson's disease patients.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3899484

A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs

27 October 2018

1 reference

12 December 2020

Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease

1 reference

12 December 2020

Quetiapine in a case with Parkinson disease and pathological gambling

1 reference

12 December 2020

Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis

1 reference

12 December 2020

Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study

1 reference

12 December 2020

Electroconvulsive Therapy in Parkinson's Disease: A Report on Five Cases

1 reference

12 December 2020

Depressive symptom profile in Parkinson's disease: a comparison with depression in elderly patients without Parkinson's disease

1 reference

12 December 2020

1 reference

12 December 2020

Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease

1 reference

12 December 2020

Pathological gambling in Parkinson disease is reduced by amantadine

1 reference

12 December 2020

Finasteride attenuates pathological gambling in patients with Parkinson disease

1 reference

12 December 2020

Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group

1 reference

12 December 2020

Risperidone in Parkinson's disease

1 reference

12 December 2020

Dysarthria During ECT Given for Parkinson's Disease and Depression

1 reference

12 December 2020

10.1007/S13311-013-0238-X

Identifiers

DOI

1 reference

1 August 2017

1 reference

1 August 2017

1 reference